RespireRx Pharmaceuticals Inc (CE) (RSPI) Share Price

What a great way to look at our situation here, faith it is !!! GLTA.....

You are exactly right.

This forum has been great to help understand a bunch about the science, the paths and where it all may lead. I think criticism of the current situation is more than fair as the frustration and testing of patience should be very understandable to all. Sometimes however, it may just be best to take a leap of faith, walk away from the frustration and just hope for the best. As the company states...

"Together, we can advance life-changing therapies, create value for our investors, and positively impact the lives of patients worldwide." And the most successful endeavours, the most successful companies generally find much truth in the word "Together".

Wishing good luck and good health to all here...

AMPA Receptor Modulation in the Treatment of High-Grade Glioma: Translating Good Science into Better Outcomes
Daniel P. Radin

Stony Brook Medical Scientist Training Program, Renaissance School of Medicine at Stony Brook University, 100 Nicolls Road, Stony Brook, NY 11794, USA
Pharmaceuticals 2025, 18(3), 384; https://doi.org/10.3390/ph18030384 (registering DOI)
Submission received: 15 January 2025 / Revised: 24 February 2025 / Accepted: 28 February 2025 / Published: 8 March 2025
Abstract
Glioblastoma (GB) treatment, despite consisting of surgical resection paired with radiation, temozolomide chemotherapy and tumor-treating fields, yields a median survival of 15–20 months. One of the more recently appreciated hallmarks of GB aggressiveness is the co-opting of neurotransmitter signaling mechanisms that normally sustain excitatory synaptic communication in the CNS. AMPA-glutamate receptor (AMPAR) signaling governs the majority of excitatory synaptic activity in the mammalian brain. AMPAR activation in glioma cells activates cellular pathways that enhance proliferation and invasion and confer resistance to approved GB therapeutics. In addition, this review places a specific emphasis on discussing the redefined GB cytoarchitecture that consists of neuron-to-glioma cell synapses, whose oncogenic activity is driven by AMPAR activation on glioma cells, and the discovery of tumor microtubes, which propagate calcium signals throughout the tumor network in order to enhance resistance to complete surgical resection and radiotherapy. These new discoveries notwithstanding, some evidence suggests that AMPAR activation can produce excitotoxicity in tumor cells. This disparity warrants a closer examination at how AMPAR modulation can be leveraged to produce more durable outcomes in the treatment of GB and tumors in peripheral organs that express AMPAR.

Keywords:

AMPA receptor; BDNF; glutamate; neurogliomal synapse; tumor microenvironment; tumor microtube
…
.
Stemming from this work, we recognized that if fluoxetine bound AMPARs at the agonist binding site, its pharmacological actions might be enhanced by concomitant treatment with an ampakine. We first demonstrated that fluoxetine possesses robust oncolytic activity to GB cells, colorectal cancer cells, and pancreas cancer cells in vitro, with all three cell lines having been previously shown to express functional AMPARs. Our subsequent studies demonstrated that CX614, an ampakine that strongly offsets receptor desensitization and prolongs agonist-induced currents [104], also reduces cancer cell viability [66]. Two ampakines that exert little effect on desensitization, CX717 and CX1739, did not alter cancer cell viability [66]. These data demonstrated that offsetting AMPAR desensitization, and in turn inducing excitotoxicity, is necessary to inhibit cancer cell viability whether the cancer cells stem from the CNS or from peripheral organs. Finally, we showed that treating all three cancer cell lines with CX614, then adding fluoxetine to the culture media five minutes later resulted in a synergistic reduction in cell viability [66], providing more evidence that fluoxetine may be inducing its oncolytic effects by AMPAR activation and subsequent excitotoxicity.

Doesn’t add up for anyone.. not when they have a “remarkable” drug candidate successful in every model of pain and deep into IND enabling with the NIH..

They have to be getting closer to culminating the IND enabling for pain as well as hearing confirmation of grant funding for IND support for epilepsy. Pressure to fix the mess is only going to grow.. there are clearly plenty of eyes watching this one..

100% agreement there LT …. They had ample opportunity to fund at that point but pointedly ran into the expert market after keeping up to date religiously prior to that ? Doesn’t add up in a good way.

This holding has been so frustrating, many of us having $$$$ tied up in this company with so many what ifs!! PATIENCE being tested that's for sure. Hope for the best !!!

I doubt that. If there is any deal in the works it will be some type of license deal upfront with milestones and control of the candidate in the hands of BP or similar.

What kind of impression is made with the lack of communication/strategy and professional presentation on top of allowing your company to "trade" on this obscure expert market? Would any funding source trust leadership to captain the ship? The DOD phase 2 news created roughly what 3-4 million in dollar volume over the course of two trading sessions. Does anyone really believe there could not have been preparations to easily fund the minor amount needed to complete SEC filings and really spend a few bucks upgrading the professional look?

Maybe any potential deal coming is an absolute monster. I think KRM-ll-81 has that look to it. But regardless deal or no deal this EM is damaging to retail and really all stakeholders as time keeps ticking away on the patent life of assets as well as adds to the debt as do any convertibles now jump to a default rate on this obscure market? That is on top of as you continually have mentioned what type of impression does this whole ordeal leave to potential partners and collaborators? What type of opportunities have been lost?

To quote others here.. "I don't get it."

Well this company and RNVA have a lot of things in common with each other.

Maybe a buyout with a cause that they stay aboard to run the trials, and see it thru.

For sure . Lottery ticket because one never knows.

Yeah may just be a dream...

I'll get off the soap box to make room for others... lol.

GLTA

Simply it would help them out alot if they had some professional leadership.

People cannot continue to make excuse after excuse for all that is lacking on the communication and presentation front and the lack of solidifying a financial path or even strategy when these candidates are now at clinical stage! And they are still fooling around on this expert market. Going to be missing 2 10-k's very soon! They should have just financed the money and stayed current a year ago and develop a professional communication and presentation strategy to put this company and their assets on the map. They would be in much better position with preclinical studies maturing and such and much higher stock price to add flexibility in their efforts as well as be able to provide a much better "look" to potential partners and financiers. I don't know what this current strategy is.

"When" this does come out of EM one never knows . Maybe a massive buy out or buyback . Gotta dream big 😀

Who wouldn't want these premier assets to be traded amongst experts!

Why not . It's in EM . In this case you never know 😀

I thought you were going for a penny... what made you try for 10x that? lol....

My shares are for sale daily at .10 cents !

Yeah. That PhD thesis which is no longer posted noted that he could not publish until 2026. I believe that was out of the UK. I am not sure if all universities require peer-revied publication to award a PhD, but UCSD sure did for my daughter. Implies that PhD candidate will not be awarded his PhD until 2026 and also access to CX9292 had a NDA associated. CX929 does not appear to have patent protection.

I don’t think they have any patent protection on old compounds academics may be studying..

I don't disagree. I'm boggled just as much.

It would help them alot to come out and say they have NDA's in place. That alone would would speak volume to the shareholder IMO. It is completely legal to say they are involved in NDA(s) . GLTA

That's what I have been saying for months. I believe Lippa, Cerna and associates have made their compounds available to universities around the world. The prices are truly cheap. I suspect there is an NDA agreement attached. So, as I said before, RSPI is getting first class, worldwide research on the cheap. The most innovative research comes from universities which RSPI has tapped into.

But look at all the peer-reviewed papers in 2024. That’s a hell of a lot of detailed work. Actually this is more than what some entire academic departments output.

Almost like they want to draw any and all attention away from themselves and the only asset currently engaged in much is KRM-ll-81. The OSA and ampakine platform has been well known for a long time and still looking to coordinate funding, so this illogical action in regard to filings, etc is most likely associated with the gabakine program. The selectivity may just put it in a select group of candidates worth quite a few pennies.. or nickels or dimes..

Thing is I think this approach will only draw more eyes here.

Oh what a mess and shame that would be and at that point all the effort to get these promising candidates to the point of clinicals would be lost

Nah it's all speculation till filling or proceedings are official made for revocation process to begin. Which should've happened already with them missing the date to file. So with limit info it may very well be a stretch but it's possible Jeff communicated a sufficient reasoning for them withholding filling. That could very well be the reason the SEC hasn't motion that filling.

What reason might that be? To accept revocation proceedings and be done with it forever. That's what's about to happen.

I share the same sentiment otherwise all this time idly wasting away makes no reasonable sense. Even if they were scammers like ENZC they utterly failed to replicate their results. Enzc tultized any lil micro news drop to allow price to rise and then slowly dilute to hell. Yet here they repeatedly have done a poor job to maximize profits or SP. Instead they tried to diminish sustained runs. Also low conversions were being made. Looks as if they had no interest in stock's performance by their management descions. Makes one curious what sort of behind the curtain scene is occurring.

I think their responses in regards to form 15 essentially suggests that they just don't want to do that...

They must have a reason to not want this trading right now. What might that reason be?

"Just my thoughts! It seems that there is not an asserted effort right now to become current"

That has now become clear. They have no clarity or strategy in regards to this EM situation. Why not take a bridge loan out or utilize their network of well off individuals to simply finance the SEC filings that is their duty and responsibility versus tarnish their image? They still could be negotiating multiple deals but with the benefit of financials in place for current and prospective shareholders as well as potential partners/resources.

Harken back to the CEO's words which IMO are very genuine and pure. KRM-ll-81 is "remarkable", successful in every single model... hoping to open "purse strings"... Couple with the gravity of progressing (closing in on culminating?) in the NIH IND enabling studies. Well this might just be THE premier preclinical candidate for pain and worth huge amounts of up front payments and milestones in any agreement. The NIH isn't going to want control of these studies coming out of their HEAL program subject to the whims of a barely functional OTC stock on some obscure trading platform.

All the items they talk about doing in the shareholder letter is ONLY possible if they have a transformative deal in the works. Conclusion: It's coming.

.0011 x .0020

It's a good faith estimate on how many shareholders on record. Mark it at 299 and post the Form 15 ASAP

That meets the requirement and once Form 15 effective, never hear from SEC again.

"Form 15 is not available to every company. You have to have less than a certain number of shareholders. We have too many if CEDE & Co (street name) does not count as a single shareholder and instead is representative of all street name holders. I don’t know the answer to that and have inquired of the SEC. No answer yet."

He should know this and he shouldn't have to ask the SEC.
1. The certain number of shareholders of record that would apply to RSPI is 300.
2. CEDE IS counted as a single shareholder.

Form 15 is almost certainly available to RSPI based on the above.

An interesting read , I know it is not RSPI just that things are moving for pain relief . GLTA
https://www.msn.com/en-us/health/other/compound-mimics-cannabis-for-pain-relief-without-the-side-effects-mouse-study-points-to-effective-opioid-alternative/ar-AA1Ajt09?ocid=hpmsn&cvid=9777833c564f4560c42530cedf7e6ceb&ei=35

With this incredible pipeline, how could it be anything else?

Yep, seems nonsensical explanations sometimes portend deals are being formulated, IMO.

Just my thoughts! It seems that there is not an asserted effort right now to become current. Could the reason be that a deal is in the works and takes priority over moving off Expert Market? Certainly makes me wonder.

Yeah that seems like a brilliant path/idea for garnering success and pushing these platforms into clinical trials...

Only going to create a bigger mess and then who is going to want to develop any of these candidates?

Yep with revocation knocking at their door, no NDA or any other issue would justify the situation they are facing

Not sure about that. The current direction is revocation of SEC registration... And how much would that mess take to recover from?

That does say a lot then now doesn't it. Not knowing what their options even are after all this time suggests they did not even care what the options would be when they entered EM. So it clearly is now a purposeful endeavour OR a method to the madness...

So now why? Is there an NDA in place related to KRM-ll-81 coming out of the NIH IND enabling studies? Or a major finance agreement in the works for the neuromodulator platforms/EndeavourRx? Or BOTH?

Well, so far as I understand form 15 would be a step in the other direction than toward becoming pink current again.

Well folks are welcome to email him and argue the point, for now we in limbo.

What the hell is he talking about that Form 15 and going pink current on OTCmarkets reporting standard may not be in the best interest of shareholders and "certainly precludes trading"?!? Trading would resume under pink current status on otcmarkets. This makes zero sense. 

It's unreal that in 9 months he hasn't fully researched every option available to them, specifically form 15, which some of us here even discussed as a potential option to forward to them in an email last June. What does this guy spend 5 days a week doing exactly?

That is complete bs that it's the same cost as $100,000 plus SEC audited fins for a fking securities lawyer to sign off on a yearly report for OTCmarkets. 

I've been in OTC's in the last 4 years where the CEO flat out said what the exact cost was to stay pink current via lawyer signing off on the yearly report and it was no where close to SEC audited fins...

But it DOES matter...

So after 9 months on this Expert Market, they do not even know if form 15 is an option... LMAO.. excuse excuse excuse.

Was there truth to the emoji people that they wanted to take company private?

Yeah, and lets not do things easy or less expensive for the company..

Of course I am invested. I managed to grab over 5 million just before EM. I suspect the 200,000 I lost on Cortex will be but a bad memory, but my wife is looking at me and saying, "a fool and his money are soon parted." I just don't think this delay in EM will matter, "there is method to this madness."

Thank you !

It is a most puzzling direction and course to get there for sure . GLTA